Can γH2AX be used to personalise cancer treatment?

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Cancer therapeutics like radiation therapy induce DNA damage, activating the DNA damage response (DDR).
• The phosphorylated histone γH2AX is an early marker of DNA double-strand breaks, a critical form of DNA damage.
• Current clinical assays for DDR aim to personalize cancer treatment by assessing damage extent and cellular response.

Purpose of the Study:

• To review the potential of γH2AX as a clinically useful biomarker for evaluating tumor and normal tissue responses to cancer therapy.
• To assess the clinical utility of measuring γH2AX in the context of DNA damage response.

Main Methods:

• Review of existing literature on γH2AX as a biomarker in cancer therapy.
• Analysis of translational research strategies for γH2AX measurement in clinical settings.
• Evaluation of the association between γH2AX and other cellular states (replication stress, hypoxia, apoptosis).

Main Results:

• γH2AX is rapidly generated following DNA double-strand breaks, indicating significant DNA damage.
• γH2AX measurement is being developed for clinical assays to assess treatment response.
• The presence of γH2AX can be influenced by other cellular conditions, potentially affecting its interpretation.

Conclusions:

• γH2AX holds significant potential as a practical biomarker for assessing tumor and normal tissue responses to cancer therapies.
• Further development of tissue sampling and assay strategies is needed to fully realize the clinical utility of γH2AX.
• Understanding the influence of confounding cellular states on γH2AX is crucial for accurate clinical application.